Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase PHASE2
Enrollment 51
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of the study is to evaluate the efficacy and the safety of abemaciclib and giredestrant before surgery in participants with early stage, oestrogen receptor-positive (ER+), human epidermal receptor 2 negative (HER2-) breast cancer (BC). Primary objective: ● To evaluate the efficacy of abemaciclib and giredestrant in complete cell cycle arrest (CCCA) rate at Week 2. Secondary objectives: * To evaluate the efficacy of abemaciclib and giredestrant in reducing the relative Ki67 expression from baseline to Week 2 * To evaluate the efficacy of abemaciclib and giredestrant in risk of recurrence (ROR) score reduction, clinical and radiological tumor response; * To evaluate the safety of abemaciclib and giredestrant. Exploratory objectives: * To evaluate the mechanisms of response and resistance to therapy; * To evaluate the correlation between Ki-67% reduction and 18- Fluorothymidine (FLT) uptake reduction; * To evaluate the pathological complete response (pCR) rate (ypT0/is, ypN0) of giredestrant plus abemaciclib

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Abemaciclib 150 MG + Giredestrant 30 MG — Enrolled patients will receive 6 cycles of treatment in the absence of disease progression or unacceptable toxicity for a total of 24 weeks (2 weeks of opportunity phase and 22 weeks of neoadjuvant phase) before surgery

Primary Outcomes

  • Efficacy of abemaciclib and giredestrant in complete cell cycle arrest (CCCA) rate (Week 2)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-27
Completion: 2027-04-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 51 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Oncotech
Principal Investigators:
  • Michelino De Laurentiis, MD (PRINCIPAL_INVESTIGATOR) - National Cancer Institute, Naples
Contact Information
Study Contact:
Michelino De Laurentiis, MD
08117770442
m.delaurentiis@istitutotumori.na.it
Claudia Von Arx, MD
0815903565
Claudia.vonarx@istitutotumori.na.it
Paolo Vigneri, MD
0957339000
vigneri.p@unict.it;vigneripaolo@gmail.com
Humanitas Istituto Clinico Catanese
Interventions
  • Drug: Abemaciclib 150 MG + Giredestrant 30 MG — Enrolled patients will receive 6 cycles of treatment in the absence of disease progression or unacceptable toxicity for a total of 24 weeks (2 weeks of opportunity phase and 22 weeks of neoadjuvant phase) before surgery
Study Locations (8 sites)
Humanitas Istituto Clinico Catanese, Catania, Catania 95045 Italy
IRCCS Ospedale Policlinico San Martino, Genova, Genova 16132 Italy
AOU Federico II, Naples, Napoli 80131 Italy
Istituto Nazionale Tumori "G. Pascale", Naples, Napoli 80131 Italy
Istituto Oncologico Veneto IRCCS, Padova, Padova 35128 Italy
IRCCS Centro di Riferimento Oncologico (CRO), Aviano, PN 33081 Italy
Fondazione Universitaria Policlinico Gemelli IRCCS, Roma, Roma 00168 Italy
Ospedale Fatebenefratelli - Isola Tiberina, Roma, Roma 00186 Italy
Eligibility Criteria
Inclusion Criteria: 1. Female patients willing and able to give written informed consent; 2. Women≥18 years of age; 3. Postmenopausal women, as defined by at least one of the following criteria: * ≥12 months of amenorrhea without an alternate medical cause plus follicle-stimulating hormone (FSH) and plasma estradiol levels within postmenopausal range by local laboratory assessment, in the absence of oral contraceptive pills, hormone replacement therapy, or gonadotropin-releasing hormone agonist or antagonist. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient; * Documented bilateral oophorectomy (≥ 14 days prior to first treatment on Day 1 of Cycle 1 and recovery from surgery to baseline); 4. Patients with cT1c (≥1.0 cm)-cT4a-c BC at presentation; a-c primary tumor must be ≥ 1.0 cm in longest diameter by ultrasound; 5. Confirmed ER+ disease by local testing on primary disease specimen: tumor must be ER ≥ 10% defined by immunohistochemistry (IHC) according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines for hormone receptor testing; 6. Confirmed HER2- disease by local testing on primary disease specimen: tumor must be HER2- according to ASCO/CAP 2023 guidelines for HER2 testing; 7. Patients with multifocal or multicentric breast cancer with at least one tumor lesion ≥1.0 cm in the longest diameter by ultrasound (reference lesion) are also eligible if the two largest tumor lesions have been histologically confirmed in the clinical evaluation and meet pathologic criteria for ER positivity and HER2 negativity. 8. No previous treatment of the disease by chemotherapy, hormone therapy, surgery or radiotherapy; 9. Patients considered appropriate for endocrine therapy according to physician judgment; 10. Ki67 score ≥10% analyzed locally and centrally confirmed. Ki67 will be analyzed locally at the time of inclusion. Patients with basal Ki67≥20% will be assessed locally and centrally confirmed retrospectively and patients with 10-19% will be assessed centrally before inclusion. 11. Patients with breast cancer eligible for primary surgery; 12. Eastern Cooperative Oncology Group (ECOG) performance status≤1; 13. Adequate bone marrow and coagulation and adequate organ function defined as follows: * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L; * Platelets count ≥100x 109/L; * Haemoglobin ≥9 g/dL (90 g/L); * Serum creatinine≤1.5 x upper limit of normal (ULN) or estimated creatinine clearance≥60 ml/min as calculated using the standard method for the institution; * Total serum bilirubin ≤1.5 x ULN (Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits could be included); * AST and/or ALT ≤3 x ULN; * Alkaline phosphatase ≤2.5 x ULN; 14. Patients able to swallow oral medications. Exclusion Criteria: 1. Patients with bilateral invasive BC; 2. Patients with metastatic BC (local spread to axillary lymph nodes is permitted (cN1\_cN2a); 3. Patients with inflammatory BC; 4. Non post-menopausal patients; 5. Patients having received previous systemic or local treatment for BC, in particular history of any prior treatment with aromatase inhibitors (AIs), tamoxifen, selective estrogen receptor down regulator, or cyclin-dependent kinase 4 and 6 inhibitors; 6. Participants who have active cardiac disease or history of cardiac dysfunction, including any of the following: * History (within 2 years of screening) or presence of idiopathic bradycardia or resting heart rate \< 50 beats per minute at screening * History of angina pectoris or symptomatic coronary heart disease within 12 months prior to randomization * History of documented congestive heart failure (New York Heart Association Class III or IV) or cardiomyopathy * QT interval corrected through use of Fridericia's formula \>470 ms for women \> 450 ms for men based on mean value of triplicate ECGs, history of long or short QT syndrome, Brugada syndrome or known history of corrected QT interval prolongation, or torsades de pointes * Presence of an abnormal ECG that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or sick sinus syndrome o Participants with first-degree heart block may be considered for inclusion following consultation with a cardiologist and determination that no additional cardiac risks are present. * Participants with pacemakers to treat more severe heart blocks and other arrhythmias are permitted. * Patients with history of well-controlled atrial fibrillation are eligible. * History (within 12 months) or presence of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such as significant structural heart disease (e.g., severe left ventricular systolic dysfunction, restrictive cardiomyopathy, hypertrophic cardiomyopathy, infiltrative cardiomyopathy, moderate-to-severe valve disease), or family history of long QT syndrome) o Clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia) should be corrected prior to enrollment. 7. Patients with known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including hepatitis; 8. Patients with history of invasive BC, ductal carcinoma in situ or lobular carcinoma in situ and other malignancy within 5 years prior to screening; 9. Patients with documented history of haemorrhagic diathesis, coagulopathy, or thromboembolism; 10. Patients on concurrent treatment with exogenous reproductive hormone therapy (for example, birth control pills, hormone replacement therapy, or megestrol acetate); 11. Patients with active systemic bacterial infection (requiring intravenous antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\]; 12. Patients with serious and/or uncontrolled pre-existing medical condition(s) that, in the judgment of the investigator, would preclude participation in this study, e.g. interstitial lung disease (ILD), severe dyspnoea at rest requiring oxygen therapy, severe renal impairment (i.e. estimated creatinine clearance \<30 ml/min), history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea); 13. Patients with known allergy or hypersensitivity to any of the study drugs or any of their excipients; 14. Patients with history of non-compliance to medical regimens; 15. Patients refusing to perform liquid and tissue biopsy; 16. Patients unwilling to or unable to comply with the protocol; 17. Patients having had major surgery within 14 days prior to screening; 18. Pregnant or lactating females prior to treatment; 19. Patients having received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to initiation of study treatment, or is currently enrolled in any other type of medical research (for example: medical device) judged by the sponsor not to be scientifically or medically compatible with this study; 20. Patients should be excluded if they have a known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
Conditions Depression, Anxiety, PTSD, Family Dynami...
Phase NA
Enrollment 74
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The proposed study draws on prior research to evaluate the feasibility, acceptability and explore preliminary effectiveness of Coffee and Family Education and Support, Version (CAFES2) using a pilot randomized type 1 hybrid effectiveness-implementation design. CAFES2 is a peer-led family and social strengthening multiple family group intervention that is designed to respond to multi-level needs of refugee families. Results of the trial will contribute to the emerging evidence base on family-based mental health interventions for refugee and newcomer communities. The trial will also generate new insights regarding implementation strategies needed to promote successful delivery of services by peer providers and the unique role of human-centered design practices for adaptation of mental health and psychosocial interventions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: CAFES2 — The adapted CAFES2 model includes an initial home visit and six multiple family group sessions delivered by peer providers. Families include at least one caregiver and one youth 12 years or older. Key model components include: 1) interfamilial discussion of stressors affecting families and family relationships, 2) psychoeducation on the effects of war and forced displacement on individuals, families and social relationships; 3) emotion regulation and self management strategies; 4) identification and activation of family and social strengths, 5) discussion of family identity and hopes for the future in resettlement and 5) discussion of social and community resources to support health and wellbeing. Each group session incorporates didactic components, family and small group discussion, skill building and separate breakout groups for adolescents and adults.

Primary Outcomes

  • Changes in feasibility of the intervention via the Feasibility of Intervention Measure (immediate post-intervention)
  • Changes in acceptability of the intervention via the Acceptability of Intervention Mesure (immediate post-intervention.)
  • Changes in PTSD symptoms via the PTSD Checklist (adult, exploratory) (baseline, immediate post-intervention and 6-week follow up)
  • Changes in adult depression and anxiety via the Hopkins Symptom Checklist (HSCL, adult, exploratory) (baseline, immediate post-intervention and 6-week follow up)
  • Changes in youth depression and anxiety via the Arab Mental Health Scale (youth, exploratory) (baseline, immediate post-intervention and 6-week follow up)
  • Changes in PTSD in children and youth via the Child Revised Impacted of Events Scale (CRIES, youth, exploratory) (baseline, immediate post-intervention and 6-week follow up)
  • Changes in post-migration stress in youth and adults via the Refugee Post-Migration Stress Scale (baseline, immediate post-intervention and 6-week follow up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-31
Completion: 2026-08-30
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 74 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Chicago
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Mary Bunn, PhD (PRINCIPAL_INVESTIGATOR) - University of Illinois at Chicago
Contact Information
Study Contact:
Mary Bunn, PhD
(312) 355-2136
mbunn@uic.edu
Mary Bunn, PhD
University of Illinios Chicago
Interventions
  • Behavioral: CAFES2 — The adapted CAFES2 model includes an initial home visit and six multiple family group sessions delivered by peer providers. Families include at least one caregiver and one youth 12 years or older. Key model components include: 1) interfamilial discussion of stressors affecting families and family relationships, 2) psychoeducation on the effects of war and forced displacement on individuals, families and social relationships; 3) emotion regulation and self management strategies; 4) identification and activation of family and social strengths, 5) discussion of family identity and hopes for the future in resettlement and 5) discussion of social and community resources to support health and wellbeing. Each group session incorporates didactic components, family and small group discussion, skill building and separate breakout groups for adolescents and adults.
Study Locations (1 sites)
University of Illinios Chicago, Chicago, Illinois 60612 United States
Eligibility Criteria
To participate in the study, the families must meet the following criteria: 1. Country of origin: Iraq, Syria, Lebanon, Jordan, Palestine or Yemen 2. refugee family living in Chicago \< three years 3. Contains at least one adult caregiver (18-55) and at least one of their children (age 12 and older) living in one household 4. One family member with \> 3 on the GHQ-12 5. able to give written informed consent. Exclusion criteria for refugee families: 1. Not from one of the following Arabic-speaking countries in the Middle East: Iraq, Syria, Jordan, Lebanon, Palestine, Yemen 2. men and women who do not have least one child aged 12 years and older living in one household 3. arrived in the U.S as a refugee greater than 3 years ago 4. persons with developmental disabilities which would preclude their participation in the adapted CAFES intervention 5. persons with severe mental health (e.g., suicidality psychotic disorder), active substance use or current in family crisis (e.g., domestic violence, divorce proceedings).
Conditions Social Avoidant Behavior, Major Depressi...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to use transcranial magnetic stimulation (TMS) to better understand the neural circuits associated with social motivation. Participant includes four study visits each that range from 1.5 - 3.0 hours in duration over approximately a one month period. The first study visit involves answering survey questions, a clinical interview, and computer tasks. The second study visit involves a magnetic resonance imaging (MRI) scan, computer tasks, and a brief TMS protocol. The second and third study visits involve a full session of TMS followed by an MRI scan and computer tasks. Adults in the Auburn/Opelika area and surrounding areas who avoid social situations, experience symptoms of depression or social anxiety, and are between 25 years old and 50 years old are eligible to participate.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Device: TMS — TMS will be administered using a Cool B-65 coil to a personalized right dlPFC region.

Primary Outcomes

  • Social motivation (Immediately post-intervention)
  • Neural circuit function (Immediately post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-30
Completion: 2029-07-31
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Auburn University
Contact Information
Study Contact:
Travis Evans, PhD
3348444550
tce0018@auburn.edu
Auburn University
Interventions
  • Device: TMS — TMS will be administered using a Cool B-65 coil to a personalized right dlPFC region.
Study Locations (1 sites)
Auburn University, Auburn, Alabama 36849 United States
Eligibility Criteria
Inclusion Criteria: * A diagnosis of Major Depressive Disorder OR a diagnosis of Social Anxiety Disorder (assessed/confirmed at screening visit). * Scoring above clinical threshold on a measure of social avoidant behavior (assessed/confirmed at phone screen). Exclusion Criteria: * Unstable psychotropic medication regimen (i.e., changes in psychotropic medication or dosage in past 3 months). * Current or lifetime diagnosis of Bipolar Disorder. * A diagnosis of substance use disorder within past 12 months. * A diagnosis of psychotic-spectrum disorder such as Schizophrenia. * Pregnancy or probable pregnancy. * Medical illness or medical treatment that would preclude or inhibit study participation. * Neurological disorder associated with brain damage. * History of seizures or head trauma with loss of consciousness \> 5 minutes. * Family history of epilepsy or personal epilepsy/seizures * Ferromagnetic implants or ferrmagnetic objects within body (e.g., pacemaker).
Conditions Breast Carcinoma
Phase PHASE3
Enrollment 300
Locations 21 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT) results and circulating tumor biomarkers, clinicians will decide which treatment to use.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Combination Product: Endocrine therapy — Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.
  • Combination Product: Endocrine therapy combined with the local treatment of FES-negative lesions — Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label. Cases with only 1 or 2 FES-negative lesions that are accessible to local treatment will be reviewed by the Centralized Reading Committee (including a radiation oncologist) to confirm the feasibility of local treatment.
  • Combination Product: Chemotherapy — Consist in single agent chemotherapy, poly-chemotherapy, or antibody-drug conjugates, per guidelines and label. Patients who are eligible (per drug label) may receive PARP inhibitor if allocated to Arm B.

Primary Outcomes

  • Progression-free survival (PFS) (54 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-05-27
Completion: 2030-09-27
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Curie
Collaborators: Zionexa
Principal Investigators:
  • Steven Le GOUILL, PhD (STUDY_DIRECTOR) - Institut Curie
Contact Information
Study Contact:
François-Clément BIDARD, PhD
+33147111515
francois-clement.bidard@curie.fr
Isabelle TURBIEZ
+33156245630
drci.promotion@curie.fr
Thomas GRELLETY, MD
tgrellety@ch-cotebasque.fr
Centre Hospitalier de la Côte basque
Interventions
  • Combination Product: Endocrine therapy — Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.
  • Combination Product: Endocrine therapy combined with the local treatment of FES-negative lesions — Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label. Cases with only 1 or 2 FES-negative lesions that are accessible to local treatment will be reviewed by the Centralized Reading Committee (including a radiation oncologist) to confirm the feasibility of local treatment.
  • Combination Product: Chemotherapy — Consist in single agent chemotherapy, poly-chemotherapy, or antibody-drug conjugates, per guidelines and label. Patients who are eligible (per drug label) may receive PARP inhibitor if allocated to Arm B.
Study Locations (21 sites)
Centre Hospitalier de la Côte basque, Bayonne, 64100 France
Institut Bergonié, Bordeaux, 33076 France
Polyclinique Bordeaux Nord Aquitaine, Bordeaux, 33077 France
Centre Francois Baclesse, Caen, 14076 France
Centre Georges Francois Leclerc, Dijon, 21079 France
Centre Oscar Lambret, Lille, 59000 France
CHU Limoges, Limoges, 87000 France
Centre Leon Bérard, Lyon, 69008 France
Institut Paoli-Calmettes, Marseille, 13009 France
Institut du Cancer Montpellier, Montpellier, 34298 France
Eligibility Criteria
Inclusion Criteria: 1. Metastatic invasive breast carcinoma of no special type. 2. Females and males of age ≥18 years. 3. Life expectancy \> 3 months. 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2. 5. Estrogen Receptor (ER)-positive (≥10%) and HER2-negative (ASCO/College of American Pathologists guidelines) breast cancer, per local assessment on the most recent breast cancer tissue examined. 6. Tumor block Formalin-Fixed Paraffin-Embedded (primary tumor or metastasis) available. 7. Patients whose disease has progressed on first line endocrine therapy with aromatase inhibitor and CDK4/6 inhibitor and who are deemed eligible, per investigator assessment, to a second line endocrine therapy. The progression on first line endocrine therapy with aromatase inhibitor and CDK4/6 inhibitor must have occurred after more than 6 months on treatment. 8. Patients with available 18F-FDG PET/CT imaging 9. Evaluable disease per RECIST criteria and measurable disease per PERCIST criteria. 10. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and any protocol-related procedures including screening evaluations. 11. Signed informed consent. 12. Patient affiliated to a social security system. Exclusion criteria: 1. Other breast cancer subtype (e.g. invasive lobular breast carcinoma). 2. One or more prior line of chemotherapy in the metastatic setting. 3. Any other systemic treatment given at metastatic disease than the first line therapy with aromatase inhibitor and CDK4/6 inhibitor. 4. Visceral crisis, per investigator's assessment. 5. Liver-only metastases. 6. Prior exposure to any authorized or experimental agent degrading the estrogen receptor (fulvestrant, oral SERDs, PROTAC, etc). 7. Pregnancy or lactation period. 8. In women of childbearing potential or premenopausal women or women with amenorrhea of less than 12 months, without adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization; LH-RH agonist cannot be considered as an efficient contraceptive measure), positive urinary or serum pregnancy test 72 hours before 18F-FES PET/CT. 9. Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease. Patients with a history of CNS metastases or cord compression are eligible if they have been treated with local therapy (e.g., radiotherapy, stereotactic surgery) and are clinically stable and off anticonvulsants and steroids for at least 4 weeks before treatment start. 10. History of previous cancer or hematological malignancy within 3 years preceding patient enrollment in the trial. Multiple primary breast cancers (controlateral/ipsilateral cancers/local relapses) are allowed pending all tumors were ER+ HER2-. 11. Persons deprived of their freedom or under guardianship or incapable of giving consent.
Conditions Hypertension, Pregnancy-Induced
Phase NA
Enrollment 618
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Nifedipine ER — Initiation of nifedipine ER postpartum at randomly assigned threshold during the first 6 weeks postpartum.

Primary Outcomes

  • Chronic hypertension (One year postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-23
Completion: 2029-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 618 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical College of Wisconsin
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigators:
  • Anna Palatnik, MD (PRINCIPAL_INVESTIGATOR) - Medical College of Wisconsin
Contact Information
Study Contact:
Alyssa M Hernandez, DO
4148055285
alyhernandez@mcw.edu
Amandla Stanley, MSN
4148056691
akstanley@mcw.edu
Lynn Yee, MD
lynn.yee@northwestern.edu
Northwestern University
Interventions
  • Drug: Nifedipine ER — Initiation of nifedipine ER postpartum at randomly assigned threshold during the first 6 weeks postpartum.
Study Locations (2 sites)
Northwestern University, Chicago, Illinois 60611 United States
Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Eligibility Criteria
Inclusion Criteria: * Hypertensive disorders of pregnancy (HDP) diagnosis, specifically gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines * Postpartum day 0-4 * Age ≥ 18 years * Able to communicate in English or in Spanish * Has an established OBGYN at an MCW or NU health system practice that has access to Epic electronic medical records. Exclusion Criteria: * Pre-gestational hypertension * Type 1 or type 2 diabetes mellitus * Admitted to intensive care unit at the time of screening * Diagnosed with HDP during postpartum readmission after discharge from delivery hospitalization * Getting discharged on the day of screening * Known allergy or contraindication to nifedipine ER * Inability or unwillingness to provide informed consent * Already taking long-acting antihypertensive medication for standard care * Maternal conditions that impact study outcomes: sickle cell disease, systemic lupus erythematosus

NYSCF Scientific Discovery Biobank

NCT06203106
Recruiting
Conditions ALS, Amyotrophic Lateral Sclerosis, Alzh...
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Other: Biological Sample Collection — Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).

Primary Outcomes

  • Biobank (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-10
Completion: 2045-11-10
Eligibility
Age: 30 Days and older
Sex: ALL
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: New York Stem Cell Foundation Research Institute
Principal Investigators:
  • Laura Andres-Martin, PhD (PRINCIPAL_INVESTIGATOR) - New York Stem Cell Foundation Research Institute
Contact Information
Study Contact:
Clinical Research Office
212-927-1801
clinicalresearch@nyscf.org
Clinical Research Office
212-927-1801
clinicalresearch@nyscf.org
New York Stem Cell Foundation Research Institute
Laura Andres-Martin, PhD
New York Stem Cell Foundation Research Institute
Interventions
  • Other: Biological Sample Collection — Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
Study Locations (1 sites)
New York Stem Cell Foundation Research Institute, New York, New York 10019 United States
Eligibility Criteria
Inclusion Criteria: * Age 30 days or older. * Diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest or healthy control. * Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing. * Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD/ADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and/or Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent. * Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental/guardian consent. * Minors undergoing blood, and/or saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent/guardian to provide consent. * Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent/guardian to provide consent. Exclusion Criteria: * Wards of the state. * For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic. * For prospective blood samples: history of coagulation disorder. * For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.
Conditions COPD, Asthma, Airway Disease
Phase Not Applicable
Enrollment 230
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

There are over 700,000 UK hospital admissions every year with lung disease symptoms. Two of the most common lung diseases contributing to these numbers are asthma and chronic obstructive pulmonary disease (COPD). The immunopathology of these diseases is not fully understood. Matched samples from the respiratory tract and circulation will be used to identify immune patterns throughout the respiratory system to elucidate the immunopathology of airway disease.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Blood samples for presence of airway disease immune endotypes (6 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-08
Completion: 2029-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 230 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guy's and St Thomas' NHS Foundation Trust
Collaborators: King's College London
Principal Investigators:
  • Mona Bafadhel, Prof (PRINCIPAL_INVESTIGATOR) - GSTT and KCL
Contact Information
Study Contact:
Gillian Radcliffe, MRes
02071888070
gillian.radcliffe@gstt.nhs.uk
Steven Cass, PhD
steven.cass@kcl.ac.uk
Gill Radcliffe
02071888070
gillian.radcliffe@gstt.nhs.uk
Guy's & St Thomas' NHS Foundation Trust
Interventions
N/A
Study Locations (1 sites)
Guy's & St Thomas' NHS Foundation Trust, London, London SE1 9RT United Kingdom
Eligibility Criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study * Aged 18 years or above * Patient: known or suspected airway disease * Healthy volunteer: considered to be in good health with no significant comorbidity (immune disorder, cancer etc.) Exclusion Criteria: * Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus. * Surgery within the preceding 6 weeks * Participants who are pregnant * History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection * Alcohol or recreational drug abuse * Diagnosis of immunodeficiency requiring treatment * Unable to provide written informed consent * Unable to read or write English * Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study
Conditions Asthma, Asthma in Children, Dyspnea, Cou...
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Bronchial asthma may present with symptoms other than the commonly reported complaints (cough, chest tightness, shortness of breath and wheezing). Less common symptoms include chronic or recurrent productive cough, inspiratory dyspnoea or recurrent pneumonia. Children presenting with these symptoms are often diagnosed with asthma bronchiale and benefit from antiasthmatic management.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Prevalence of typical and atypical asthma symptoms in children with asthma bronchiale (Initial checkup with asthma symptom documentation and answering the ISAAC questionaire. Suspection on asthma diagnosis and initiation of therapy and scheduled follow-up within 3 months to confirm the diagnosis.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-01
Completion: 2027-06-01
Eligibility
Age: 3 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Charles University, Czech Republic
Principal Investigators:
  • Jana Tukova, MD,PhD (PRINCIPAL_INVESTIGATOR) - Charles University, Czech Republic First Faculty of Medicine, Prague
Contact Information
Study Contact:
Jana Tukova
+420608116653
tukovajana@seznam.cz
Ilona Trtikova, Mgr., PhD
+420224965613
ilona.trtikova@lf1.cuni.cz
First faculty of Medicine, Charles university.
Interventions
N/A
Study Locations (1 sites)
First faculty of Medicine, Charles university., Prague, 128 00 Czechia
Eligibility Criteria
Inclusion Criteria: \- Child 3 - 18 years old, first evaluation in pulmonary outpatient clinic for any of the following respiratory symptoms: cough, shortness of breath, chest tightness, wheezing, recurrent lower respiratory tract and lung infections, dyspnoea of any type, pathological listening findings. Exclusion Criteria: * Other documented chronic respiratory, cardiovascular, neurological, genetic, infectious, metabolic disease, significant immaturity or other disease that may be accompanied by respiratory symptoms.
Conditions Pediatric Asthma
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The overarching goal of this study is to optimize pediatric asthma care and to continuously evaluate variations/innovations of the care (including transformation to remote eHealth care). Primary Objectives within cmRCT cohort: * Provide a framework for multiple randomized (eHealth) interventions for asthmatic children * Generate short- and long-term data on Quality of life (QoL), asthma outcomes (asthma control, lung function), quality of care, self-management capacity, healthcare use, and therapy compliance in a representative secondary care pediatric asthma cohort. Secondary Objectives within cmRCT cohort: * Evaluate current pediatric asthma care at the Pediatric department of Medisch Spectrum Twente, in order to explore possible improvements for the pediatric asthma care. * Compare the short and long-term asthma outcomes between the eHealth care path and the outpatient care path. * Compose patient risk profiles that include both personal, clinical and exposome markers and clinical asthma endpoints (for example clinical admission/exacerbations).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Other: video directly observed therapy (vDOT) — The first intervention of within the CIRCUS study is video directly observed therapy (vDOT). The intervention consists of taking recording of daily inhalation use and receiving four feedback sessions of an asthma nurse based on these home recordings.

Primary Outcomes

  • Asthma control (monthly (until the patient turns 18 years old, has no astma diagnosis anymore or is no longer under treatment of the MST hospital, whichever came first, assessed up to 168months))
  • Pediatric Asthma Quality of Life (once per 6 months (until the patient turns 18 years old, has no astma diagnosis anymore or is no longer under treatment of the MST hospital, whichever came first, assessed up to 168months))
  • Quality of care (once per 6 months (until the patient turns 18 years old, has no astma diagnosis anymore or is no longer under treatment of the MST hospital, whichever came first, assessed up to 168months))
  • Self-management capacity (once per 6 months (until the patient turns 18 years old, has no astma diagnosis anymore or is no longer under treatment of the MST hospital, whichever came first, assessed up to 168months))
  • Healthcare use (continuous (until the patient turns 18 years old, has no astma diagnosis anymore or is no longer under treatment of the MST hospital, whichever came first, assessed up to 168months))
  • Wheather data (daily (until the patient turns 18 years old, has no astma diagnosis anymore or is no longer under treatment of the MST hospital, whichever came first, assessed up to 168months))
  • Air quality (daily (until the patient turns 18 years old, has no astma diagnosis anymore or is no longer under treatment of the MST hospital, whichever came first, assessed up to 168months))
  • Pollen (daily (until the patient turns 18 years old, has no astma diagnosis anymore or is no longer under treatment of the MST hospital, whichever came first, assessed up to 168months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-01
Completion: 2034-04-01
Eligibility
Age: 4 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mattienne van der Kamp
Contact Information
Study Contact:
CIRCUSstudy
+31 53 487 23 10
circusstudie@mst.nl
Job van der Palen, Full professor
0534872000
mst@mst.nl
Medisch Spectrum Twente
Mattienne Ricard van der Kamp, PhD
Medisch Spectrum Twente
Interventions
  • Other: video directly observed therapy (vDOT) — The first intervention of within the CIRCUS study is video directly observed therapy (vDOT). The intervention consists of taking recording of daily inhalation use and receiving four feedback sessions of an asthma nurse based on these home recordings.
Study Locations (1 sites)
Medisch Spectrum Twente, Enschede, Overijssel 7512KZ Netherlands
Eligibility Criteria
Inclusion Criteria: * Is 4 to 18 years old * Is patient at the children's department at Medisch Spectrum Twente at moment of inclusion * Is diagnosed with asthma by a pediatrician following the Global Initiative for Asthma(GINA) guidelines 2022 \[8\]: \*Medical history fitting asthma diagnosis: * Based on (typical) symptoms: (nighttime) wheezing, dyspnea, coughing (triggered by either viral infections, exercise, allergens or weather changes) * (Possibly) supplemented with a family history/atopy AND \*Spirometry variable expiratory airflow limitation by at least one of these criteria: * FEV1/FVC reduced compared to lower limit of normal(Z-score ≤ -1.64) * Positive bronchodilator responsiveness(increase FEV1\>12%) * Positive Exercise Challenge Test (ECT)(decrease FEV1≥ 13%) * Excessive variation in lung function (LF) between tests from different dates (variation FEV1\>12% pred) Exclusion Criteria: * The child and/or parent(s) has/have insufficient command of the Dutch language resulting in the insufficient ability to understand and/or answer questions
Conditions Breast Cancer
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test the safety of the use of non-thermal plasma (NTP, an ionized gas) on the tumor bed after the removal of the tumor in breast cancer patients. The main questions it aims to answer are: * To determine the safe and tolerable dose of NTP in patients with breast cancer; * To assess the safety and tolerability of NTP; * To assess the cosmetic effects of NTP treatment in patients with breast cancer. Participants will receive one treatment of the tumor bed after the removal of their breast tumor.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Convertible Plasma Jet — NTP will be applied to the patients using the Convertible Plasma Jet (CPJ, NexPlasmaGen Inc.)

Primary Outcomes

  • Incremental increase of NTP dose to reach maximum safe dose. (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-07
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators: Ozmosis Research Inc., Quebec Breast Cancer Foundation
Contact Information
Study Contact:
Nawel Belaiboud
514-890-8000
nawel.belaiboud.chum@ssss.gouv.qc.ca
Centre Hospitalier de l'Université de Montréal - CHUM
Lydia Tkalec
5148908000
lydia.tkalec.chum@ssss.gouv.qc.ca
Centre Hospitalier de l'Université de Montréal - CHUM
Philip Wong, MD
Centre Hospitalier de l'Université de Montréal - CHUM
Interventions
  • Device: Convertible Plasma Jet — NTP will be applied to the patients using the Convertible Plasma Jet (CPJ, NexPlasmaGen Inc.)
Study Locations (1 sites)
Centre Hospitalier de l'Université de Montréal - CHUM, Montreal, Quebec h2X0A9 Canada
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years at the time of signing study consent. 2. ECOG ≤2. 3. Patient with T1-4 breast cancer for groups A and B; patient with T1/T2 breast cancer for group C (based on physical exam, not radiological measurements). 4. Patient is scheduled to undergo a lumpectomy. Exclusion Criteria: 1. Prior treatment for the tumor of interest (including chemotherapy, immunotherapy, radiotherapy). 2. Patient planning to or undergoing intraoperative radiotherapy. 3. Diabetes (types I and II). 4. Hypercortisolism. 5. Collagen vascular disease. 6. Patient requiring systemic corticosteroids at physiologic doses exceeding 10 mg/day of prednisone or its equivalent. 7. Patient receiving daily chemotherapy for rheumatological conditions. 8. Pregnancy (a urine pregnancy test must be obtained for non-sterile women of childbearing potential prior to surgery).
Conditions Breast Cancer
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this non randomized clinical trial, with pre- and post-intervention evaluation, longitudinal, with prospective data collection is to evaluate the effects of dance as a therapeutic intervention in breast cancer patients undergoing surgical treatment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Dance — Dance protocol

Primary Outcomes

  • ROM (Pre-intervention and after 16 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-01
Completion: 2026-05-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AC Camargo Cancer Center
Principal Investigators:
  • Letícia Cardenas, PHD (PRINCIPAL_INVESTIGATOR) - AC Camargo Cancer Center
Contact Information
Study Contact:
Letícia Cardenas, PHD
5511985742277
leticia.cardenas@accamargo.org.br
Letícia Cardenas, PHD
+5511985742277
leticia.cardenas@accamargo.org.br
AC Camargo Cancer Center
Interventions
  • Other: Dance — Dance protocol
Study Locations (1 sites)
AC Camargo Cancer Center, São Paulo, 01525-001 Brazil
Eligibility Criteria
Inclusion Criteria: * patients diagnosed with breast cancer * undergone surgical resection * after medical referral for physiotherapy * and physiotherapeutic assessment Exclusion Criteria: * patients with another previous oncological diagnosis * previous neuromuscular diseases * patients who do not agree to take part in the study * or the impossibility of carrying out the muscle strength assessment and/or other assessments
Conditions Suicide, Bereavement
Phase NA
Enrollment 169
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the RISE study is to examine how the 24-hour rhythm of sleep and social activity relate to mood and suicidal ideation among older adults that recently lost a spouse or life partner.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: WELL Behavioral Probe — Participant record the timing and regularity of sleep, meals, and social activity twice daily, for 3 months, using a digital diary. Participants also receive weekly motivational health coaching.

Primary Outcomes

  • Change in suicidal ideation over 12 months using the Beck Scale for Suicidal Ideation (BSSI) (Baseline and at month 1, 2, 3, 6, 9, and 12.)
  • Change in perceived loneliness over 12 months using the UCLA Loneliness Scale (Baseline and at month 1, 2, 3, 6, 9, and 12.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-20
Completion: 2029-12-01
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 169 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Sarah Stahl, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Emilee Croswell, BA
4124408418
croswellej@upmc.edu
Sarah Stahl, PhD
sts80@pitt.edu
Emilee Croswell
412-440-8418
RISE_research@pitt.edu
University of Pittsburgh (UPMC)
Interventions
  • Behavioral: WELL Behavioral Probe — Participant record the timing and regularity of sleep, meals, and social activity twice daily, for 3 months, using a digital diary. Participants also receive weekly motivational health coaching.
Study Locations (1 sites)
University of Pittsburgh (UPMC), Pittsburgh, Pennsylvania 15212 United States
Eligibility Criteria
Older adults who recently lost their spouse or life partner and are high risk for suicidal thoughts and/or behavior. Inclusion Criteria: 1. Bereaved \< or = to 12 months from spousal/partner loss 2. \> or = to 65 years old 3. Verified history of suicide attempt/attempts and/or current or past history of Major Depressive Disorder/Major Depressive Episode (MDD/MDE) (without psychotic features), or history of depression severe enough to trigger treatment, or current subsyndromal depression (\> or = to 9 HDRS) 4. No diagnosis of schizophrenia/schizoaffective disorders/bipolar/current psychosis 5. Does not reside in nursing home 6. Not a current shift worker 7. No major cognitive impairment: TICS score of \> or = to 27 Exclusion Criteria: 1. Bereaved \>12 months from spousal/partner bereavement 2. \< 65 years old 3. Patient is not spousal/partner bereaved (ex: parent, sibling, etc.) 4. Prior diagnosis of schizophrenia/schizoaffective disorders/bipolar/current psychosis or medications listed indicate diagnosis of these disorders/MDD or MDE with psychotic features 5. Major cognitive impairment: TICS score of \<27 6. Current shift worker 7. Resides in a nursing home 8. Unstable medical condition (e.g., unstable angina, end stage renal disease)